GlobeNewswire

Cannara annonce son entrée à la Bourse de Toronto
26/02/2026
MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
26/02/2026
TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s [...]
Addgene Appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships
26/02/2026
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Addgene, an organization committed to accelerating discovery and innovation by providing a vast catalog of expertly curated and quality-controlled research tools [...]
Mixie Technologies, Inc. (OTC: PHCG) Secures Minority Ownership Stake in Mixie Realty LLC
26/02/2026
Transaction expands Mixie’s platform strategy into immersive real estate visualization and technology-enabled property management DENVER, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mixie Technologies, Inc. (OTC: PHCG), formerly [...]
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
Conference call today at 9:00 am ET Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $ [...]
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
26/02/2026
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational discipline Strong revenue outlook, procedure growth, expanding [...]
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin [...]
Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
26/02/2026
Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million ; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025 Eighth consecutive [...]
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will [...]
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
26/02/2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
26/02/2026
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and [...]
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
26/02/2026
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an [...]
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
26/02/2026
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase [...]
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM ® Net [...]
Trading by management and close relations of management
26/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
26/02/2026
Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the [...]
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
26/02/2026
Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U.S. subsidiary [...]
Pulselight to host senior health leaders for panel on ‘efficiency drive’ to reduce NHS waste and duplication
26/02/2026
Former UK Health Minister Lord Bethell and former Deputy Chief Medical Officer Professor Sir Jonathan Van-Tam, join Pulselight for panel on unlocking NHS efficiency LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pulselight, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum